Navigation Links
SomaLogic announces agreement with leading global pharma company to accelerate R&D
Date:10/18/2011

Boulder CO, October 18, 2011 SomaLogic, Inc., announced today that it has entered into a multi-year research agreement with Novartis to use its unique proprietary proteomics technology to accelerate Novartis' drug discovery and development efforts.

"We are excited by this opportunity to work with Novartis' world-class researchers to help them define robust biomarkers, validate novel drug targets, and even develop companion clinical diagnostics," said Larry Gold, CEO of SomaLogic. "We believe that our technology is uniquely able to address the significant drug discovery and development challenges currently faced by biopharmaceutical companies."

Terms of the agreement were not disclosed.

SomaLogic's proprietary proteomic platform is built on two decades of painstaking work to develop an entirely new generation of specific protein-binding reagents that would break open protein biomarker discovery and development in order to drive new diagnostic and therapeutic opportunities. At the heart of SomaLogic's technology are "SOMAmers" (Slow-Offrate Modified Aptamers), an entirely novel class of protein-binding reagents. SOMAmers offer a uniquely powerful combination of specific binding to individual proteins and facile nucleic acid-based quantification, allowing accurate detection and measurement of literally thousands of proteins over a vast range of concentrations in just a few drops of blood or other tissues.


'/>"/>

Contact: Fintan Steele, Ph.D.
fsteele@somalogic.com
617-816-9834
SomaLogic, Inc.
Source:Eurekalert

Page: 1

Related biology news :

1. SomaLogic and New England Biolabs announce agreement to use SOMAmers for multiple PCR products
2. SomaLogic researchers describe revolutionary new approach to protein analysis and application to early diagnosis of lung cancer
3. Trudeau Institute announces its latest discovery in the fight against tuberculosis
4. Biophysical Society announces 2012 Society Fellows
5. White House announces that 2 UCSB faculty members will receive US presidential science awards
6. FASEB announces new client: The Histochemical Society
7. MedNet Solutions Announces the Latest Release of iMedNet EDC
8. FASEB MARC program announces the travel award recipients for the 2011 Leadership Development and Grant Writing Seminar for graduate students, postdoctoral fellows and new assistant professors
9. Trudeau Institute announces new discovery in battle against infections
10. Wiley-Blackwell announces continued growth in impact factor journals
11. The Society for Nutrition Education (SNE) announces Helen Denning Ullrich Award of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
(Date:4/17/2014)... in about one per eight hundred births, Down syndrome ... genetic cause of intellectual disability. It results from a ... third copy of chromosome 21 (1% of the human ... team in the Department of Genetic Medicine and Development ... published in Nature , shed light on how ...
(Date:4/17/2014)... to produce hydrogen sulfide in order to properly multiply ... from the Center for Craniofacial Molecular Biology at the ... Songtao Shi, principal investigator on the project, said the ... the flow of calcium ions. The essential ions activate ... or the creation of new bone tissue, and keeps ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... released by the University of Minnesota Boynton Health Service ... nation to conduct a comprehensive survey on the health ... survey. Although the study is focused on students from ... national health trends for college students, says Dr. Ed ...
... 25% of Europes medium sized household appliances and 40% ... leaving substantial room for improvement, according to a study ... consortium. Small appliances, with a few exceptions, are close ... long-term collection rate targets of around 60% for small ...
... -- In response to the need for localized efforts ... threatened staghorn coral, Diego Lirman, Ph.D., and James Herlan, ... Marine and Atmospheric Science (RSMAS) have established an ... The goals of the coral nursery are to ...
Cached Biology News:University of Minnesota releases first ever comprehensive report of the health of college students 2University of Minnesota releases first ever comprehensive report of the health of college students 3University of Minnesota releases first ever comprehensive report of the health of college students 4University of Minnesota releases first ever comprehensive report of the health of college students 5Great potential to improve collection, recycling of Europe's electronic waste, says UN report 2Great potential to improve collection, recycling of Europe's electronic waste, says UN report 3New south Florida nursery to focus on staghorn corals 2
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up their ... of them wrote: "Take better care of my furry companion." Nowadays ... clothes and top-brand carrying cases to take the little canine or ... also feel compelled to buy some pricey toys at the pet ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... 30 DOR BioPharma, Inc. (OTC Bulletin Board: SNGX), a ... corporate name change from DOR BioPharma, Inc. to Soligenix, Inc. ... change, the Company,s shares of common stock will immediately begin ... , "We are pleased to announce the name ...
... STOCKHOLM, September 30 Nobelprize.org has ... official news about the 2009,Nobel Prize Announcements as soon as ... or Medicine, will be made on October 5, (see,the full ... exact,moment the announcements are made public in the following ways: ...
... 30 Amicus Therapeutics (Nasdaq: FOLD ) today announced ... (1-deoxynojirimycin HCl), its investigational drug in development for the treatment ... is to evaluate the pharmacokinetics of AT2220 in muscle tissue ... Administration (FDA) has agreed to Amicus, proposal for the Phase ...
Cached Biology Technology:DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 2DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 3DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 4Nobelprize.org Expands Channels and News Services for the 2009 Nobel Prize Announcements 2Nobelprize.org Expands Channels and News Services for the 2009 Nobel Prize Announcements 3Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 2Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 3Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 4